Clinical Study on the Treatment of Non-Alcoholic Fatty Liver Disease with Polyene Phosphatidylcholine Combined with Zhibitai
Objective To explore the clinical study of treating non-alcoholic fatty liver disease patients with polyene phosphatidylcholine combined with Zhibitai.Methods From January 2022 to August 2023,98 patients with NAFLD who were treated at Anyang People's Hospital were selected and randomly divided into a monotherapy group(49 cases,polyene phosphatidylcholine)and a combination therapy group(49 cases,polyene phosphatidylcholine combined with Zhibitai).Liver function,blood lipid indicators,serum diamine oxidase,D-lactic acid,cytokine levels,and treatment effects were observed.Results After treatment,the levels of alanine aminotransferase(ALT),gamma-glutamyl transpeptidase(GGT),and aspartate aminotransferase(AST)in the combination therapy group were lower than those in the monotherapy group,with statistically significant differences(P＜0.05).The levels of total cholesterol(TC),triglycerides(TG),and low-density lipoprotein(LDL)in the combination therapy group were lower than those in the monotherapy group,while the level of high-density lipoprotein(HDL)was higher than that in the monotherapy group,with statistically significant differences(P＜0.05).The levels of serum diamine oxidase(DAO),D-lactic acid(D-LA),interleukin-6(IL-6),and tumor necrosis factor-alpha(TNF-α)in the combination therapy group were lower than those in the monotherapy group,with statistically significant differences(P＜0.05).The effective rate of treatment in the combination therapy group was higher than that in the monotherapy group,with statistically significant differences(P＜0.05).Conclusion The treatment of NAFLD patients with polyene phosphatidylcholine combined with Zhibitai can significantly improve liver function and blood lipids,enhance the therapeutic effect,and has good clinical application value.
万方数据
维普
